Prednisolone or pentoxifylline for alcoholic hepatitis

Thursz, MR; Richardson, P; Allison, M; Austin, A; Bowers, M; Day, CP; Downs, N; Gleeson, D; MacGilchrist, A; Grant, A; Hood, S; Masson, S; McCune, A; Mellor, J; O'Grady, J; Patch, D; Ratcliffe, I; Roderick, P; Stanton, L; Vergis, N

doi:https://www.dx.doi.org/10.1056/NEJMoa1412278

File(s)

nejmoa1412278.pdf (524.09 KB)

Published version

Author(s)

Thursz, MR

Richardson, P

Allison, M

Austin, A

Bowers, M

more

Type

Journal Article

Abstract

Alcoholic hepatitis is a clinical syndrome characterized by jaundice and liver impairment that occurs in patients with a history of heavy and prolonged alcohol use. The short-term mortality among patients with severe disease exceeds 30%. Prednisolone and pentoxifylline are both recommended for the treatment of severe alcoholic hepatitis, but uncertainty about their benefit persists.

Date Issued

2015-04-23

Date Acceptance

2015-04-23

Citation

New England Journal of Medicine, 2015, 372 (17), pp.1619-1628

URI

http://hdl.handle.net/10044/1/25846

DOI

https://www.dx.doi.org/10.1056/NEJMoa1412278

ISSN

1533-4406

Publisher

Massachusetts Medical Society

Start Page

1619

End Page

1628

Journal / Book Title

New England Journal of Medicine

Volume

372

Issue

17

Copyright Statement

License URL

http://www.rioxx.net/licenses/all-rights-reserved

Subjects

Science & Technology

Life Sciences & Biomedicine

Medicine, General & Internal

General & Internal Medicine

Publication Status

Published